Mesalamine in the treatment and maintenance of remission of ulcerative colitis
- 1 March 2012
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Clinical Pharmacology
- Vol. 5 (2), 113-123
- https://doi.org/10.1586/ecp.12.2
Abstract
Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC. There are multiple formulations of mesalamine available, primarily differentiated by their means of delivering active mesalamine to the colon. Mesalamine has been demonstrated in randomized controlled trials to induce both clinical response and remission, and maintain clinical remission, in these patients. It has few serious adverse effects and is generally well tolerated by patients. The main areas of uncertainty with use of mesalamine in patients with UC center on the optimal dose for induction of response, how to maintain patient adherence and the role of mesalamine in cancer chemoprophylaxis. Generic forms of mesalamine have yet to be approved by regulatory bodies in the USA.Keywords
This publication has 85 references indexed in Scilit:
- MMX® MesalazineDrugs, 2011
- Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2010
- Review article: understanding adherence to medication in ulcerative colitis – innovative thinking and evolving conceptsAlimentary Pharmacology & Therapeutics, 2010
- Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized studyInflammatory Bowel Diseases, 2010
- Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized studyInflammatory Bowel Diseases, 2010
- Mesalamine Inhibits Epithelial β-Catenin Activation in Chronic Ulcerative ColitisGastroenterology, 2010
- Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussionWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2010
- Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled StudyDigestive Diseases and Sciences, 2009
- Outcome measurement in clinical trials for ulcerative colitis: towards standardisationTrials, 2007
- PPAR as a new therapeutic target in inflammatory bowel diseasesGut, 2006